Head-to-head evidence
Dostarlimab vs Retifanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline
NCT03739710 · Phase 2 · completed
An open-label platform master study whose posted primary outcome is only the number of participants randomized across sub-studies; no comparative efficacy result for the dostarlimab-containing regimens is reported on the record. With no usable result and no blinding, this is weak evidence.
Next expected readout: November 2026 · NCT05565378 (registry estimate)
Retifanlimab
Marketed by Incyte
NCT04205812 · Phase 3 · completed
Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).
Next expected readout: December 2027 · NCT07219576 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Retifanlimab's landscape